Trident Texofab IPO Details: Price, Dates & Financials

Shares reserved for the market maker in Trident Texofab IPO: Up to ₹0 Cr. The market maker provides two-way quotes after listing to keep the stock liquid.

Pre-issue shareholding: 2,819,875 shares. Post-issue shareholding: 3,995,875 shares.

Trident Texofab IPO is a Fresh Capital issue. Issue type: Fixed Price IPO. Face value is ₹10.

The UPI mandate for Trident Texofab IPO needs to be accepted by 26 Sep 2017. Approve the mandate request in your UPI app before the deadline, otherwise your bid may be rejected.

The Red Herring Prospectus (RHP) of Trident Texofab IPO is available on the website of the lead manager and the stock exchange (BSE SME) — see the lead manager links on the main page.

The DRHP is the initial offer document filed for regulatory review, while the RHP includes updated disclosures, final issue details, and the price band (when announced). Comparing both documents helps investors identify changes in the Trident Texofab IPO's financial information, risks, and offer terms before investing in the Trident Texofab IPO. Reviewing both documents provides a clearer understanding of the Trident Texofab IPO before making an investment decision.

The DRHP and RHP of the Trident Texofab IPO disclose potential risks related to the company's business, financial performance, legal matters, and industry conditions. Reviewing these documents helps investors identify potential concerns about the Trident Texofab IPO, evaluate the Trident Texofab IPO's risk factors, and make a more informed decision before investing in the Trident Texofab IPO.